Allison Kurian conclusions about Germline genetic testing use and results after a cancer diagnosis. ASCO #ASCO23 Myriad Genetics

Kurian et al presentation conclusions #ASCO23: Genetic testing use fell well below recommended guidelines from 2013-2121. 😞 Male breast 50% Ovarian 39% Pancreatic 6% (100% is Recommend)😳 Complete data published in JAMA today. Congrats to all authors! Myriad Genetics

Hear how Dr Westgate has implemented genetic testing routinely into her practice. #ASCO23 Myriad Genetics

There is an under testing problem- specifically in populations that have been historically underrepresented. We MUST do better for our patients ASCO Myriad Genetics #ASCO23 Allison Kurian ASBrS SGO

This is why germline testing NEEDS to occur independent of tumor testing results - many patients with cancer meet criteria just based on the cancer they have ! Myriad Genetics #ASCO23 ASCO

PRS and association with BC presented by Olufunmilayo Olopade Myriad Genetics #ASCO23

PRS initially was not validated in those populations outside of European populations but we’ve done a lot of work to be able to provide this information for ALL patients - Myriad Genetics #asco23

We have proven that combined residual polygenic risk scores (TC plus PRS) is more accurate than TC alone in predicting risk Myriad Genetics #ASCO23

Dr Olopade discussing the Myriad Genetics combined PRS with TC 8 for ALL ancestries stratifies breast cancer risk beyond clinical factors currently used in the clinic. #ASCO23

#ASCO23 day 4 included another pair of sneakers and 11,300 steps. The next question is, do I ramp up my last day of #ASCOsteps by taking the train to the airport or do I Uber? Myriad Genetics

The last supper at #ASCO23 with Myriad Genetics med affairs 😍 amazing team work !!!

Dr. Jonathan Tward (Jonathan Tward), Huntsman Cancer Institute at University of Utah Health, presented a poster on "Predicting Absolute Benefit in Risk of Metastasis of ADT added to Radiation Therapy in Patients with Newly Diagnosed #ProstateCancer” Read the full abstract: meetings.asco.org/abstracts-pres… #ASCO23

So excited to be presenting in October on this very interesting topic. I think I've now read just about every publication about MBD4 and polyposis risks. 😅 Come join us!

Check out our poster “Active Surveillance Selection and Durability in Men with NCCN Intermediate Risk, Localized Prostate Cancer Who Had Genetic Testing” being presented at #WSAUA23. @ProlarisTest Myriad Genetics

I may not have been able to find FedEx East/Lakeside to pick up my poster, but I did find a nice view! Come see me tomorrow at poster ASD35 Barriers to Care: When insurance does not cover hereditary cancer genetic testing in unaffected individuals. #NSGC23 Myriad Genetics

Come join us on Friday night! For each attendee Myriad Genetics will be donating to two patient advocacy groups! #NSGC23

A big thank you to all the #geneticcounselors who came out for the #NSGC23 First Time Attendee Reception, but the conversation doesn’t end tonight. We look forward to connecting with you again at booth #317 - we’re here all week! 🎉#GeneChat Learn more: myriad.com/nsgc/

#NSGC23 hasn't even officially started but my futile search for FedEx at McCormick Place led to 9,778 #NSGCsteps. The question is, will tomorrow bring more or less?! Myriad Genetics team, you got your sneakers ready?

News: We're excited to announce the launch of the Myriad Collaborative Research Registry™ (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million

We are proud to join Illumina Ambry Genetics Quest Diagnostics Oncology Volpara Health AliveAndKickn and @FacingOurRisk to help increase evidence-based access to genetic testing for people with or at risk of hereditary cancers. Read the press release: brnw.ch/21wItBK